Anti-selection in digital life distribution needs a concrete operating process in life and health reinsurance, not just policy statements. Here is what that process actually looks like.
Anti-selection in digital life distribution is becoming a real executive risk in life and health reinsurance as accelerated underwriting scales faster than fraud controls. Here is how the problem starts.
Anti-selection in digital life distribution deserves direct board scrutiny in life and health reinsurance. Here is how boards should evaluate whether this risk is genuinely under control.
Anti-selection in digital life distribution needs a clear executive decision framework in life and health reinsurance. Here is how CUOs should think about the tradeoff between speed and verification.
Anti-selection in digital life distribution erodes return on capital in life and health reinsurance well before it shows up as an obvious claims spike. Here is how the erosion actually happens.
Behavioral lapse models that fail in stress need specific, repeatable operating controls, not just a stronger model, to catch drift early and keep pricing and reserving aligned with real experience.
The P&L impact of behavioral lapse models that fail in stress is easy to underestimate because it moves through reserves, DAC amortization, and capital charges before it ever reaches the headline numbers.
Boards overseeing life and health reinsurers need specific, evidence-based questions to confirm management actually controls behavioral lapse models that fail in stress, not just assurances that it does.
Behavioral lapse models that fail in stress cut across underwriting, finance, claims, and risk, and an unclear ownership structure is often the real reason the failure goes uncorrected for so long.
Behavioral lapse models that fail in stress are not a modeling footnote, they are a direct earnings and capital problem for life and health reinsurers. Here is why the failure happens and what it costs.
Biometric risk correlation after population events needs a clear data-ownership and escalation model. Here is how reinsurers should structure ongoing monitoring for this exposure.
Biometric risk correlation after population events is the diagnosis problem growing quietly behind biometric-informed reinsurance portfolios. Here is why individually strong risk signals can become correlated portfolio risk overnight.
Biometric risk correlation after population events does not erode margin gradually the way isolated mispricing does. Here is why it hits a reinsurance portfolio all at once, and how to size that exposure.
Biometric risk correlation after population events raises a direct balance-sheet question boards are not yet asking. Here is how much exposure it can create, and how to size it.
Biometric risk correlation after population events raises questions most vendor pricing models have never had to answer. Here is the executive decision framework a Chief Actuary should apply.
Claims leakage in high-volume health portfolios stops being a recurring surprise once it becomes a measured, repeatable process with clear metrics, sampling standards, and accountability.
Claims leakage in high-volume health portfolios is not just a primary insurer problem, it directly shapes the loss experience, pricing, and treaty terms reinsurers depend on.
Boards overseeing life and health reinsurers should not tolerate claims leakage in high-volume health portfolios without specific, quantified evidence of detection and remediation from management.
Claims leakage in high-volume health portfolios needs a specific executive decision framework across underwriting, claims, and finance, not a single department quietly trying to fix it alone.
Claims leakage in high-volume health portfolios can quietly turn a fast-growing, seemingly profitable book into a margin problem, since growth simply scales the leakage along with the premium.
Catching longevity concentration across pension transactions before it becomes a capital problem takes an operating process built for aggregation, not just per-deal review. Here is how to build it.
Longevity concentration across pension transactions builds quietly as large deals stack onto a small pool of reinsurers. Here is why the risk gets missed until it is already large.
Boards overseeing life and health reinsurance need an explicit risk-appetite limit for longevity concentration across pension transactions, not just trust in transaction-level review. Here is the test to apply.
Longevity concentration across pension transactions forces executive teams to decide how much correlated exposure to one demographic driver is acceptable. Here is the framework for that call.
Longevity concentration across pension transactions turns a single demographic surprise into a correlated capital event. Here is how that earnings volatility builds and how to measure it.
Solving medical trend outpacing treaty economics takes more than a diagnosis, it takes operating controls that catch the gap before it reaches the executive committee. Here is what those controls look like.
Medical trend outpacing treaty economics quietly erodes life and health reinsurance margins long before a loss ratio confirms the damage. Here is how to spot the gap early.
Boards overseeing life and health reinsurance need a clear answer to what breaks first if medical trend outpacing treaty economics continues unchecked. Here is the governance question worth asking now.
Medical trend outpacing treaty economics forces a decision only executives can make: reprice, restructure, or hold. Here is the framework CFOs and CROs need to make that call.
Medical trend outpacing treaty economics does more than shrink margin, it quietly ties up capital that could otherwise support new business. Here is how to measure the drag.
Mortality improvement assumptions after structural shocks need an operating fix, not just a strategic decision. Here is the practical process for catching and correcting drift before the next renewal.
Mortality improvement assumptions after structural shocks quietly erode margin and capital in life and health reinsurance long after the acute event has passed. Here is how to size the real cost.
Mortality improvement assumptions after structural shocks deserve direct board scrutiny in life and health reinsurance. Here are the questions a board should be asking and why.
Mortality improvement assumptions after structural shocks stop matching real experience because the tables were built for calmer health and social conditions. Here is why the gap opens and how reinsurers should read it.
Mortality improvement assumptions after structural shocks force a genuine executive decision, not just an actuarial update. Here is the decision framework reinsurance CEOs and CUOs need to use.
Underwriting evidence that ages too quickly is an operating-controls problem as much as a data problem. Here is how better workflow design closes the gap for reinsurers.
Underwriting evidence that ages too quickly does not just create a diagnosis problem, it quietly erodes margin and distorts capital across a reinsurance treaty. Here is how to size that cost.
Underwriting evidence that ages too quickly deserves a standing board-level scenario, not a one-time review. Here is the exercise reinsurance leaders should run and repeat.
Underwriting evidence that ages too quickly is a growing risk-diagnosis problem for life and health reinsurers. Here is why point-in-time evidence stops describing the applicant almost immediately, and what that means for treaty risk.
Underwriting evidence that ages too quickly needs a clear decision owner. Here is the executive decision framework reinsurers need to control this exposure before it becomes a renewal surprise.